Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
This study will evaluate long-term safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic NET patients, who who have not progressed during 12 months of combination therapy with pasireotide LAR and everolimus
Neuroendocrine Tumors
DRUG: RAD001|DRUG: SOM230
Number of Participants with Adverse Events and Serious Adverse Enents as a Measure of Safety and Tolerability, up to 4 years|Number of Participants with abnormal laboratory and ECG results as a Measure of Safety and Tolerability, up to 4 years
investigator-assessed progression free survival (PFS), up to 4 years|best overall response, up to 4 years
This study will evaluate long-term safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic NET patients, who who have not progressed during 12 months of combination therapy with pasireotide LAR and everolimus